FibroBiologics, Inc. (NasdaqCM: FBLG)
Health Care · Biotechnology · US
$1.41
+33.02% today · -91.4% 1Y
FibroBiologics, Inc. (NasdaqCM: FBLG) operates in the Biotechnology industry within the Health Care sector. The company is valued at $7.06M and employs 15 people.
Over the last twelve months the share price has lost 91.4%, trading between 0.62 and 12.80.
Tweenvest scores FibroBiologics, Inc. across four factors: quality 25/100. Its strongest factor is quality.
FBLG price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $7.06M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -4.77
- Dividend yield
- —
- Beta (5Y)
- 1.22
- 52-week high
- $12.80
- 52-week low
- $0.62
- Avg volume (3M)
- —
- Shares outstanding
- 6.66M
- Employees
- 15
- Next earnings
- —
About FibroBiologics, Inc.
FibroBiologics, Inc. operates as a clinical-stage biopharmaceutical firm, advancing therapies derived from fibroblasts toward commercialization within the United States. The company's pipeline includes CybroCell, currently being developed to address degenerative disc disease; CYMS101, targeting multiple sclerosis; and CYWC628 for wound repair. Further demonstrating its broad scope, early-stage investigations are underway for CYTER915, aimed at restoring or enhancing thymus and/or spleen function; CYPS317, for psoriasis; and TCB190, designed to combat specific cancers. FibroBiologics was founded in 2021 and is situated in Houston, Texas.
- ISIN
- US31573L2043
- Founded
- 2021
- Listed since
- Feb 1, 2024
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $464.58B | $262.90 | -1.09% |
| Amgen Inc.NasdaqGS: AMGN | $238.06B | $440.34 | -0.43% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $183.64B | $148.09 | -0.01% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.72B | $547.29 | -1.01% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $81.36B | $814.79 | -2.25% |
| argenx SEENXTBR: ARGX | $65.40B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $59.75B | $149.66 | -5.77% |
| CSL LimitedASX: CSL | $59.19B | AU$172.44 | -0.69% |
Figures last refreshed Aug 18, 2026.